

Gatipotuzumab

Cat. No.:	HY-P99634
CAS No.:	1264737-26-9
Target:	Mucin
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) ^{[1][2]} .
IC₅₀ & Target	MUC1 ^[1]
In Vitro	Gatipotuzumab (PankoMab) strongly binds to a short MUC1 peptide of 30 amino acids comprising 1.5 TRs when it is glycosylated with GalNAcα at the T of the PDTRP-sequence, but not if the same peptide is not glycosylated ^[2] . Gatipotuzumab (PankoMab) (1 h) has a high-affinity towards tumour cells (K _D of 0.91, 3.03, 3.84 and 7.14 nM towards NM-D4, ZR75-1, MCF-7 and T-47D, respectively) ^[2] . Gatipotuzumab (PankoMab) (0-5 µg/mL; 4 h) shows specific anti-tumor antibody-dependent cell cytotoxicity activity ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. *European Journal of Cancer*, 2020, 138: S5-S6.

[2]. Danielczyk A, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. *Cancer Immunol Immunother*. 2006 Nov;55(11):1337-47.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA